There are 1105 resources available
134O - Asia subgroup overall survival and long-term follow-up results of the phase IIb HERIZON-BTC-01 study: Zanidatamab in previously treated human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC)
Presenter: Jin Won Kim
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 374O and 375O
Presenter: Jung-Yun Lee
Session: Proffered Paper session: Gynaecological cancers
Resources:
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session: Gynaecological cancers
Resources:
Webcast
Invited Discussant 133O and 134O
Presenter: Lorenza Rimassa
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Webcast
Welcome and introduction
Presenter: Soo Chin Lee
Session: Pfizer - Cyclin' Through Innovation: Next Generation CDKs in HR+ MBC
Resources:
Webcast
Challenges in frontline treatment of HR+ MBC
Presenter: Soo Chin Lee
Session: Pfizer - Cyclin' Through Innovation: Next Generation CDKs in HR+ MBC
Resources:
Webcast
Mechanisms of resistance to CDK4/6 inhibition in HR+ MBC
Presenter: Yoichi Naito
Session: Pfizer - Cyclin' Through Innovation: Next Generation CDKs in HR+ MBC
Resources:
Webcast
Innovation in CDK inhibition in HR+ MBC
Presenter: Antonio Giordano
Session: Pfizer - Cyclin' Through Innovation: Next Generation CDKs in HR+ MBC
Resources:
Webcast
Q&A
Session: Pfizer - Cyclin' Through Innovation: Next Generation CDKs in HR+ MBC
Resources:
Webcast